Drug Profile


Alternative Names: VCH-222; VX-222

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator ViroChem Pharma
  • Developer Vertex Pharmaceuticals
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 26 Jul 2016 Trek Therapeutics acquires lomibuvir from Vertex Pharmaceuticals
  • 15 May 2014 Vertex Pharmaceuticals completes a phase II trial in Hepatitis C (treatment-naive, combination therapy) in USA, Canada, Germany, Poland and United Kingdom (NCT01516918)
  • 01 Feb 2014 Vertex Pharmaceuticals terminates phase II ZENITH trial in Hepatitis C (treatment-naive, in combination with telapravir) in US and New Zealand (NCT01080222)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top